DE60229867D1 - Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen - Google Patents

Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen

Info

Publication number
DE60229867D1
DE60229867D1 DE60229867T DE60229867T DE60229867D1 DE 60229867 D1 DE60229867 D1 DE 60229867D1 DE 60229867 T DE60229867 T DE 60229867T DE 60229867 T DE60229867 T DE 60229867T DE 60229867 D1 DE60229867 D1 DE 60229867D1
Authority
DE
Germany
Prior art keywords
peyer
flake
cells
ligands against
targeted ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60229867T
Other languages
German (de)
English (en)
Inventor
Daniel O'mahony
Imelda Lanbkin
Lisa Higgins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merrion Research Ill Ltd
Original Assignee
Merrion Research Ill Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrion Research Ill Ltd filed Critical Merrion Research Ill Ltd
Application granted granted Critical
Publication of DE60229867D1 publication Critical patent/DE60229867D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
DE60229867T 2001-07-02 2002-06-28 Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen Expired - Lifetime DE60229867D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30259101P 2001-07-02 2001-07-02
PCT/IB2002/003401 WO2003004517A2 (en) 2001-07-02 2002-06-28 Peyers's patch and/or m-celle targeting ligands

Publications (1)

Publication Number Publication Date
DE60229867D1 true DE60229867D1 (de) 2008-12-24

Family

ID=23168408

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60229867T Expired - Lifetime DE60229867D1 (de) 2001-07-02 2002-06-28 Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen

Country Status (8)

Country Link
US (3) US6916789B2 (https=)
EP (1) EP1432729B1 (https=)
JP (1) JP4383855B2 (https=)
AT (1) ATE414100T1 (https=)
AU (1) AU2002326070A1 (https=)
CA (1) CA2451741C (https=)
DE (1) DE60229867D1 (https=)
WO (1) WO2003004517A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521737B1 (en) * 1995-11-10 2003-02-18 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
DE60229867D1 (de) * 2001-07-02 2008-12-24 Merrion Res Iii Ltd Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen
EP1631582A2 (en) * 2003-06-10 2006-03-08 University of Saskatchewan Chimeric adenovirus capsid proteins
AU2012201102B2 (en) * 2004-06-23 2014-05-08 Ferguson, Ian Andrew Agents and methods for early diagnosis and monitoring of Alzheimer's disease and other neurological disorders
DE102005031755B9 (de) * 2005-07-01 2010-04-08 Technische Universität Dresden Salmonella spp. bindende Peptide, dafür kodierende Nukleinsäuren, deren Verwendungen und Verfahren und Kits zur Anreicherung, Immobilisierung und zum Nachweis von Salmonella spp.
WO2007137174A2 (en) * 2006-05-18 2007-11-29 The Ohio State University Research Foundation Compositions and methods for the detection of vulnerable plaque
PL2897620T3 (pl) 2012-09-21 2020-11-02 Intensity Therapeutics, Inc Sposób leczenia nowotworu złośliwego
JP6618892B2 (ja) 2013-04-23 2019-12-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 細菌バイオフィルムの遺伝的リプログラミング
EP3280397A4 (en) * 2015-04-06 2018-08-22 President and Fellows of Harvard College Biosynthetic amyloid-based materials displaying functional protein sequences
WO2017201428A1 (en) 2016-05-19 2017-11-23 President And Fellows Of Harvard College Methods of making gels and film using curli nanofibers
TW201829470A (zh) 2016-10-26 2018-08-16 廖朝暐 用於免疫增強的融合胜肽及使用其增強誘發免疫反應的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR940010862B1 (ko) * 1985-02-05 1994-11-18 씨네겐 바이오로지칼즈, 인코포레이티드 유용한 메탈로프로테이나제 억제제 씨퀀스 재조합 벡터계의 제조를 위한 dna 재조합 방법
IL84167A (en) * 1986-10-24 1991-04-15 Southern Res Inst Oral delivery of bioactive agents to and through the peyer's patch by use of microencapsulation
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
GB9201139D0 (en) * 1992-01-20 1992-03-11 Connaught Lab Synthetic peptides for a rubella vaccine
AU3937693A (en) 1992-04-10 1993-11-18 Brigham And Women's Hospital Methods and compositions for oral delivery of therapeutic agents
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
AU2159895A (en) * 1994-03-11 1995-09-25 Ariad Pharmaceuticals, Inc. Methods and materials for identifying inhibitors of molecular interactions mediated by sh3 domains
US5831008A (en) * 1994-08-18 1998-11-03 La Jolla Cancer Research Foundation Retinoblastoma protein-interacting zinc finger proteins
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
IE80466B1 (en) 1995-11-10 1998-07-29 Elan Corp Plc Peptides which enhance transport across tissues and methods of identifying and using the same
AU705688B2 (en) * 1995-11-10 1999-05-27 Cytogen Corporation Peptides which enhance transport across tissues and methods of identifying and using the same
US6261787B1 (en) 1996-06-03 2001-07-17 Case Western Reserve University Bifunctional molecules for delivery of therapeutics
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
JP4129298B2 (ja) * 1997-05-15 2008-08-06 サイトジェン コーポレーション 胃腸管（ｇｉｔ）輸送受容体に結合するランダムペプチド、及び関連した方法
WO2001027154A2 (en) * 1999-09-27 2001-04-19 Mahony Daniel J O Membrane translocating peptide drug delivery system
JP2001245675A (ja) * 1999-12-28 2001-09-11 Kyogo Ito 腫瘍抗原
CN1323825A (zh) * 2000-05-16 2001-11-28 上海博德基因开发有限公司 一种新的多肽——人网格蛋白轻链9和编码这种多肽的多核苷酸
AU2002254161A1 (en) * 2001-03-12 2002-09-24 Montana State University-Bozeman M cell directed vaccines
CA2443644A1 (en) * 2001-04-04 2003-01-16 Elan Corporation, Plc Genetic analysis of peyers's patches and m cells and methods and compositions targeting peyer's patches and m cell receptors
DE60229867D1 (de) * 2001-07-02 2008-12-24 Merrion Res Iii Ltd Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen

Also Published As

Publication number Publication date
US6916789B2 (en) 2005-07-12
US20050227924A1 (en) 2005-10-13
CA2451741A1 (en) 2003-01-16
WO2003004517A2 (en) 2003-01-16
EP1432729B1 (en) 2008-11-12
AU2002326070A1 (en) 2003-01-21
US20030096354A1 (en) 2003-05-22
EP1432729A2 (en) 2004-06-30
JP4383855B2 (ja) 2009-12-16
ATE414100T1 (de) 2008-11-15
WO2003004517A3 (en) 2004-04-29
CA2451741C (en) 2014-02-18
JP2005503782A (ja) 2005-02-10
US7485321B2 (en) 2009-02-03
US20100016549A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
CY1107467T1 (el) Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
TR200101307T2 (tr) Antranilik asit amidler ve ilaç olarak kullanılmaları.
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
SE9504661D0 (sv) New compounds
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
BRPI0413449A (pt) compostos de quinoxalina
ES2191208T3 (es) Oxiimino-pregnano-carbolactonas.
EA200300929A1 (ru) Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv
TW200509892A (en) Novel aminobenzophenone compounds
SE9802729D0 (sv) Novel Compounds
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
TR199901949T2 (xx) Lemfositik t�m�rler i�in �areler.
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
SE9802208D0 (sv) Novel compounds
DE60229867D1 (de) Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
DE60142913D1 (de) Arzneilösungen enthaltend modafinilverbindungen
SE0003476D0 (sv) Compounds
CY1105020T1 (el) Υποκαταστατες διαζεπανες
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
DE60310742D1 (de) Extrakt mit antitumoraler und antitoxischer wirkung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition